» Articles » PMID: 12126753

Role of Reactive Metabolites of Oxygen and Nitrogen in Inflammatory Bowel Disease

Overview
Date 2002 Jul 20
PMID 12126753
Citations 130
Authors
Affiliations
Soon will be listed here.
Abstract

The inflammatory bowel diseases (IBD; Crohn's disease, ulcerative colitis) are a collection of chronic idiopathic inflammatory disorders of the intestine and/or colon. Although the pathophysiology of IBD is not known with certainty, a growing body of experimental and clinical data suggests that chronic gut inflammation may result from a dysregulated immune response to normal bacterial antigens. This uncontrolled immune system activation results in the sustained overproduction of reactive metabolites of oxygen and nitrogen. It is thought that some of the intestinal and/or colonic injury and dysfunction observed in IBD is due to elaboration of these reactive species. This review summarizes the current state-of-knowledge of the role of reactive oxygen species and nitric oxide in the pathophysiology of IBD.

Citing Articles

Investigation into recent advanced strategies of reactive oxygen species-mediated therapy based on Prussian blue: Conceptualization and prospect.

Kwon H, Jung Y, Jeon H, Han H Bioact Mater. 2025; 48:71-99.

PMID: 40034810 PMC: 11874232. DOI: 10.1016/j.bioactmat.2025.01.023.


Children who develop celiac disease are predicted to exhibit distinct metabolic pathways among their gut microbiota years before diagnosis.

Kelley K, Dogru D, Huang Q, Yang Y, Palm N, Altindis E Microbiol Spectr. 2025; 13(3):e0146824.

PMID: 39902908 PMC: 11878042. DOI: 10.1128/spectrum.01468-24.


Cell-derived biomimetic drug delivery system for inflammatory bowel disease therapy.

Yang W, Lin P, Gao R, Fang Z, Wang Z, Ma Z Mater Today Bio. 2024; 29:101332.

PMID: 39606424 PMC: 11600033. DOI: 10.1016/j.mtbio.2024.101332.


Therapeutic role of extracellular vesicles from human umbilical cord mesenchymal stem cells and their wide therapeutic implications in inflammatory bowel disease and other inflammatory disorder.

Azhar Ud Din M, Wan A, Chu Y, Zhou J, Yan Y, Xu Z Front Med (Lausanne). 2024; 11:1406547.

PMID: 39139783 PMC: 11319305. DOI: 10.3389/fmed.2024.1406547.


Nanoparticle-Based Drug Delivery Systems for Inflammatory Bowel Disease Treatment.

Gao J, Li J, Luo Z, Wang H, Ma Z Drug Des Devel Ther. 2024; 18:2921-2949.

PMID: 39055164 PMC: 11269238. DOI: 10.2147/DDDT.S461977.